From GlobeNewswire: 2024-11-21 09:00:00

The Mesenchymal Stem Cells (MSC) Market was valued at USD 3.2 Billion in 2023 and is projected to reach USD 9.72 Billion by 2032, with a compound annual growth rate of 13.20% from 2024 to 2032. Aging population, regenerative medicine advancements, and biotech innovations are driving this growth.

Technological advancements like 3D bioprinting and CRISPR gene editing are accelerating growth in the MSC market. Streamlined regulatory approaches have led to the approval of MSC therapies, with firms innovating proprietary treatments for degenerative and chronic diseases management.

Allogenic MSCs currently lead the market, driven by strong demand and advanced technologies. The segment accounted for 57% of the market share in 2023. On the other hand, the autologous MSC segment is expected to grow at a fast 14.43% CAGR from 2024 to 2032 due to increasing demand for personalized treatments.

In 2023, the products segment dominated the MSC market, representing 80% of total revenue. The rising demand for readily available MSC therapies, particularly for tissue regeneration and immune modulation, has bolstered this segment’s growth. The services segment is expected to grow at a CAGR of 15.65% from 2024 to 2032, driven by the need for patient-specific MSC therapies.

The Bone Marrow segment led the MSC market with a 44% revenue share in 2023, thanks to its consistent adoption for hematological disorders. On the other hand, the Cord Blood segment is expected to experience rapid growth, with a projected CAGR of 15.66% from 2024 to 2032, due to its potential for immune modulation and regenerative therapies. North America leads the Mesenchymal Stem Cells (MSC) market with 47% revenue in 2023, driven by high demand and advanced healthcare infrastructure. Asia Pacific is set for rapid growth with a projected CAGR of 14.87% between 2024-2032 due to increasing trends in regenerative medicine. Significant market players are investing in MSC research and therapeutic applications.

In 2024, Cellcolabs and REPROCELL partnered to distribute MSCs globally. Stemedica Cell Technologies launched a Phase IIb/III clinical trial for intravenous allogeneic MSCs for chronic ischemic stroke. The MSC market is witnessing key developments to enhance research and therapeutic applications.

The market for MSCs is characterized by top-down and bottom-up research methodologies, data validation, and primary interviews. Market dynamics impact analysis includes driving factors, PESTLE analysis, and Porter’s Five Forces model. Statistical insights cover incidence, prevalence, prescription trends, healthcare spending, and production volumes.

The competitive landscape of the MSC market includes major companies, market share analysis, product benchmarking, strategic initiatives, and technological advancements. Segmentation by region and type, along with market positioning and branding, provide a comprehensive overview. Regional analysis and company profiles offer deeper insights into market trends and players.

S&S Insider is a global market research and consulting agency providing clients with accurate market data and consumer insights. Through various techniques like surveys and focus groups, S&S Insider aims to empower clients to make informed decisions in a rapidly changing market landscape. Contact for customized research and expert analysis.



Read more at GlobeNewswire: Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72